৳ 533.33/unit
Pack: ৳ 3,199.98
৳ 533.33/unit
Pack: ৳ 3,199.98
At a glance
Nirmatrelvir + Ritonavir is an antiviral for mild-to-moderate COVID-19. Nirmatrelvir inhibits SARS-CoV-2 main protease (Mpro) and Ritonavir is a CYP3A inhibitor that increases nirmatrelvir plasma concentrations.
Indications
- Mild-to-moderate COVID-19 in adults and pediatric patients (12 years+, ≥40 kg) with positive SARS-CoV-2 test and at high risk for progression to severe COVID-19
Pharmacology
Nirmatrelvir binds to SARS-CoV-2 Mpro enzyme to inhibit viral polyprotein processing, stopping viral replication. Ritonavir inhibits CYP3A enzyme to increase nirmatrelvir plasma concentrations.
Dosage
Adults and Children (12 years+, ≥40 kg):
- 300 mg Nirmatrelvir (2 x 150 mg) + 100 mg Ritonavir (1 tablet), taken together twice daily for 5 days
Moderate Renal Impairment (eGFR ≥30-<60 mL/min):
- 150 mg Nirmatrelvir (1 tablet) + 100 mg Ritonavir, twice daily for 5 days
Side effects
Side Effects (>1%):
- Dysgeusia (taste alteration)
- Diarrhea
- Hypertension
- Myalgia
Use in pregnancy
Use in Pregnancy: No human data on nirmatrelvir in pregnancy; observational studies on ritonavir have not shown increased risk of major birth defects.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Potential for drug interactions; review concomitant medications
- Ritonavir may cause hepatic transaminase elevations, clinical hepatitis and jaundice
- Risk of HIV-1 drug resistance in uncontrolled or undiagnosed HIV-1 infection
Overdose effects
Limited information on overdose; symptomatic treatment.
Storage conditions
Do not store above 30°C; keep in a dry place, protect from light; keep out of reach of children.